Y Intercept Hong Kong Ltd Makes New $304,000 Investment in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Y Intercept Hong Kong Ltd purchased a new stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 26,071 shares of the company’s stock, valued at approximately $304,000.

Other institutional investors also recently modified their holdings of the company. Handelsbanken Fonder AB boosted its position in shares of Intellia Therapeutics by 7.1% in the fourth quarter. Handelsbanken Fonder AB now owns 34,700 shares of the company’s stock valued at $405,000 after acquiring an additional 2,300 shares during the period. LMG Wealth Partners LLC acquired a new stake in Intellia Therapeutics in the 4th quarter worth $130,000. Rhumbline Advisers increased its holdings in shares of Intellia Therapeutics by 2.1% during the 4th quarter. Rhumbline Advisers now owns 166,248 shares of the company’s stock worth $1,938,000 after purchasing an additional 3,499 shares during the period. Allspring Global Investments Holdings LLC raised its position in shares of Intellia Therapeutics by 14.0% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 12,863 shares of the company’s stock valued at $157,000 after buying an additional 1,582 shares during the last quarter. Finally, Entropy Technologies LP bought a new stake in shares of Intellia Therapeutics in the fourth quarter valued at about $175,000. Institutional investors own 88.77% of the company’s stock.

Insider Transactions at Intellia Therapeutics

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of the business’s stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $12.18, for a total value of $326,509.26. Following the transaction, the chief executive officer now owns 941,115 shares in the company, valued at approximately $11,462,780.70. The trade was a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last ninety days, insiders sold 29,000 shares of company stock worth $352,551. 3.20% of the stock is currently owned by insiders.

Intellia Therapeutics Trading Down 3.7 %

Shares of NASDAQ NTLA opened at $9.10 on Wednesday. The stock has a market cap of $942.00 million, a price-to-earnings ratio of -1.67 and a beta of 1.97. The stock’s 50-day moving average is $10.74 and its 200 day moving average is $15.36. Intellia Therapeutics, Inc. has a 1-year low of $8.30 and a 1-year high of $32.42.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on NTLA shares. Truist Financial cut their price target on shares of Intellia Therapeutics from $90.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday. William Blair reaffirmed a “neutral” rating and issued a $14.00 price target on shares of Intellia Therapeutics in a research note on Monday, November 18th. Citigroup increased their price objective on Intellia Therapeutics from $12.00 to $14.00 and gave the stock a “neutral” rating in a research note on Friday, February 28th. Morgan Stanley cut Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and cut their price objective for the company from $56.00 to $11.00 in a report on Monday, January 27th. Finally, Chardan Capital lowered their target price on shares of Intellia Therapeutics from $91.00 to $68.00 and set a “buy” rating on the stock in a report on Friday, February 28th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Intellia Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $38.00.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.